相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preliminary crystallographic studies of an anti-HIV-1 protease antibody that inhibits enzyme activity
Julien Lescar et al.
PROTEIN SCIENCE (2010)
Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients
Claudine Duvivier et al.
AIDS (2009)
Analysis and characterization of dimerization inhibition of a multi-drug-resistant Human Immunodeficiency Virus Type 1 protease using a novel size-exclusion chromatographic approach
David A. Davis et al.
BIOCHEMICAL JOURNAL (2009)
Dimer Disruption and Monomer Sequestration by Alkyl Tripeptides Are Successful Strategies for Inhibiting Wild-Type and Multidrug-Resistant Mutated HIV-1 Proteases
Ludovic Bannwarth et al.
BIOCHEMISTRY (2009)
Sidechain-linked inhibitors of HIV-1 protease dimerization
Michael J. Bowman et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Toward the Design of Mutation-Resistant Enzyme Inhibitors: Further Evaluation of the Substrate Envelope Hypothesis
Visvaldas Kairys et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2009)
Metabolic syndrome associated with HIV and highly active antiretroviral therapy
Giuseppe Barbaro et al.
CURRENT DIABETES REPORTS (2009)
Darunavir A Review of its Use in the Management of HIV Infection in Adults
Kate McKeage et al.
DRUGS (2009)
HIV protease inhibitors: recent clinical trials and recommendations on use
Jose Vicente Fernandez-Montero et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis
Juan Macias et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Design of HIV-1 Protease Inhibitors with Pyrrolidinones and Oxazolidinones as Novel P1′-Ligands To Enhance Backbone-Binding Interactions with Protease: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies∞
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Design of HIV Protease Inhibitors Based on Inorganic Polyhedral Metallacarboranes
Pavlina Rezacova et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir
Klara Grantz Saskova et al.
JOURNAL OF VIROLOGY (2009)
In search of small molecules blocking interactions between HIV proteins and intracellular cofactors
Katrien Busschots et al.
MOLECULAR BIOSYSTEMS (2009)
Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody
Julien Lescar et al.
PROTEIN SCIENCE (2009)
The history of antiretrovirals: key discoveries over the past 25 years
Erik De Clercq
REVIEWS IN MEDICAL VIROLOGY (2009)
The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications
Oliver P. Flint et al.
TOXICOLOGIC PATHOLOGY (2009)
Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies
Vanda Bartonova et al.
ANTIVIRAL RESEARCH (2008)
Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy
Awewura Kwara et al.
CLINICAL INFECTIOUS DISEASES (2008)
The structural biology of HIV assembly
Barbie K. Ganser-Pornillos et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2008)
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
Jane E. Mallewa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Inorganic polyhedral metallacarborane inhibitors of HIV protease:: A new approach to overcoming antiviral resistance
Milan Kozisek et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Solution Kinetics Measurements Suggest HIV-1 Protease Has Two Binding Sites for Darunavir and Amprenavir
Andrey Y. Kovalevsky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants
Michael D. Altman et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Ninety-nine is not enough:: Molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region
Milan Kozisek et al.
JOURNAL OF VIROLOGY (2008)
Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir
Klara Grantz Saskova et al.
PROTEIN SCIENCE (2008)
Approaches to the design of HIV protease inhibitors with improved resistance profiles
Sergei V. Gulnik et al.
CURRENT OPINION IN HIV AND AIDS (2008)
Protease inhibitor therapy in resource-limited settings
Julian H. Elliott et al.
CURRENT OPINION IN HIV AND AIDS (2008)
Molecular analysis of the HIV-1 resistance development:: Enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants
Milan Kozisek et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients
Mike Youle
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1
Serge Dandache et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization
Yasuhiro Koh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV
Richard Hazen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir
Sherie Masse et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease
Madhavi N. L. Nalam et al.
JOURNAL OF VIROLOGY (2007)
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN:: a randomised controlled phase III trial
Jose Valdez Madruga et al.
LANCET (2007)
Fosamprenavir calcium plus ritonavir for HIV infection
Harrys A. Torres et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2007)
Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations
S. Muzammil et al.
JOURNAL OF VIROLOGY (2007)
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis
Sripriya Chellappan et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet et al.
LANCET (2007)
Targeting structural flexibility in HIV-1 protease inhibitor binding
Victor Hornak et al.
DRUG DISCOVERY TODAY (2007)
The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy
Andrea F. Armstrong et al.
DALTON TRANSACTIONS (2007)
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism
Monique Nijhuis et al.
PLOS MEDICINE (2007)
Disruption of the HIV-1 protease dimer with interface peptides: Structural studies using NMR spectroscopy combined with [2-C-13]-Trp selective labeling
Silvia Frutos et al.
BIOPOLYMERS (2007)
Boron units as pharmacophores - New applications and opportunities of boron cluster chemistry
Zbigniew J. Lesnikowski
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS (2007)
Inhibitors of HIV-1 protease: Current state of the art 10 years after their introduction. from Antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors
Antonio Mastrolorenzo et al.
CURRENT MEDICINAL CHEMISTRY (2007)
No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations
Selwyn H. Lowe et al.
HIV CLINICAL TRIALS (2006)
Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease
David A. Davis et al.
ANTIVIRAL RESEARCH (2006)
Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring
Tomas Cihlar et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114
Andrey Y. Kovalevsky et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance
P. D. Yin et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system
Avindra Nath et al.
CURRENT OPINION IN NEUROLOGY (2006)
Molecular tongs containing amino acid mimetic fragments:: New inhibitors of wild-type and mutated HIV-1 protease dimerization
Ludovic Bannwarth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance
C de Mendoza et al.
AIDS (2006)
Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: A single mode of inhibition for the three HIV enzymes ?
Maria-Jose Camarasa et al.
ANTIVIRAL RESEARCH (2006)
Understanding and avoiding antiretroviral adverse events
S Shibuyama et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy
D. A. Wohl et al.
CLINICAL INFECTIOUS DISEASES (2006)
Tipranavir - A novel nonpeptidic protease inhibitor of HIV
Jennifer R. King et al.
CLINICAL PHARMACOKINETICS (2006)
From nonpeptide toward noncarbon protease inhibitors:: Metallacarboranes as specific and potent inhibitors of HIV protease
P Cígler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The management of HIV-1 protease inhibitor pharmacokinetic interactions
A Winston et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: Clinical impact and molecular mechanisms
MA Winters et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir
RM Kagan et al.
PROTEIN SCIENCE (2005)
New approaches toward anti-HIV chemotherapy
E De Clercq
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Crystal structure of a cross-reaction complex between an anti-HIV-1 protease antibody and an HIV-2 protease peptide
P Rezacova et al.
JOURNAL OF STRUCTURAL BIOLOGY (2005)
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir
C Le Tiec et al.
CLINICAL PHARMACOKINETICS (2005)
Herpesvirus protease inhibition by dimer disruption
N Shimba et al.
JOURNAL OF VIROLOGY (2004)
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor
NM King et al.
JOURNAL OF VIROLOGY (2004)
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (< 50 cells/mu L)
M Floridia et al.
HIV MEDICINE (2004)
Kinetics of the dimerization of retroviral proteases:: The fireman's grip and dimerization
M Ingr et al.
PROTEIN SCIENCE (2003)
Fullerene derivatives: an attractive tool for biological applications
S Bosi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2003)
Novel bis-tetrahydrofuranylurethane-containin nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro
Y Koh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease
J Dumond et al.
BIOCHEMICAL PHARMACOLOGY (2003)
The etiology of urolithiasis in HIV infected patients
RB Nadler et al.
JOURNAL OF UROLOGY (2003)
Prodrugs of HIV protease inhibitors
P Vierling et al.
CURRENT PHARMACEUTICAL DESIGN (2003)
Lopinavir/ritonavir - A review of its use in the management of HIV infection
RS Cvetkovic et al.
DRUGS (2003)
Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy
MP Dubé et al.
CLINICAL INFECTIOUS DISEASES (2002)
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to 150V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro
MF Maguire et al.
JOURNAL OF VIROLOGY (2002)
Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes
M Prabu-Jeyabalan et al.
STRUCTURE (2002)
Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody
P Rezacova et al.
STRUCTURE (2001)
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
DJ Kempf et al.
JOURNAL OF VIROLOGY (2001)
Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition
DA Judd et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2001)
Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults
JM Kilby et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
BA Larder et al.
AIDS (2000)
Targeting the dimerization interface for irreversible inhibition of HIV-1 protease
R Zutshi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
Nelfinavir - An update on its use in HIV infection
A Bardsley-Elliot et al.
DRUGS (2000)
How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease
M Prabu-Jeyabalan et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
分享论文
